OCT 2014 ARTICLE LIST >>
PharmaTutor (October- 2014)
ISSN: 2347 - 7881
(Volume 2, Issue 10)
Received On: 31/07/2014; Accepted On: 10/08/2014; Published On: 01/10/2014
AUTHORS:
Patel Divya .A.1*, Raj.Hasumati1, Patel Roshni2
1Department of Quality Assurance, Shree Dhanvantary Pharmacy College, Kim, Surat, Gujarat
2Piooner College of pharmacy, Baroda, Gujarat
*divyapatel388@gmail.com
ABSTRACT:
Edaravone is a potent free radical scavenger (antioxidant) mainly use in the form of injection. It is used in the treatment of various cardiovascular diseases like acute ischemic stroke as well as in gastrointestinal injuries. This review article represent the various analytical methods which has been reported for estimation of edaravone in biological matrix as well as in synthetic mixture.The spectrophotometric techniques like fluorescent assay and ratio derivative spectroscopy; Chromatogrraphic methods like HPLC, HPTLC and RP HPLC were reported.
How to cite this article: DA Patel, R Hasumati, R Patel; Edaravone: A Review on Analytical Method and its Determination in Biological Matrix and Synthetic Mixture; PharmaTutor; 2014; 2(10); 80-84
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1. Edaravone Drug Info.(database available on internet):Chemical Book. Available from: chemicalbook.com/ProductMSDSDetailCB1287462_EN.htm
2. Edaravone Drug Info.(database available on internet):Lookchem. Available from: lookchem.com/Edaravone/
3. Toshiaki W, Munenori T, Satoru T. The Novel Antioxidant Edaravone: From Bench to Bedside. Cardiovascular Therapeutics; 20098,26:101–114.
4. Doherty AM. Annual Reports in Medicinal Chemistry. Boston: Academic Press; 2002, 37.
5. Watanabe T. et al. Research and development of the free radical scavenger edaravone as a neuroprotectant. Yakugaku Zasshi (in Japanese); 2004, 124(3):99–111.
6. Higashi Y, Jitsuiki D, Chayama K, Yoshizumi M. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases. Recent Patents on Cardiovascular Drug Discovery; 2006, 1(1):85–93.
7. Yoshida H. et al.Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury. CNS Drug Reviews; 2006, 12(1):9–20.
8. Yuan WJ. et al. Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons. BMC Neuroscience; 2008, 9:75.
9. Kawasaki T. et al. Protective effect of the radical scavenger edaravone against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum. European Journal of Pharmacology; 2006, 542(1-3):92–99.
10. Kawasaki T. et al. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced neurotoxicity in the substantianigra but not the striatum. The Journal of Pharmacology and Experimental Therapeutics; 2007, 322(1):274–281.
11. Yokoyama H. et al. Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice. Journal of Neural Transmission; 2008, 115(6):831–842.
12. Yokoyama H. et al. Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice. Metabolic Brain Disease; 2008, 23(3):335–349.,
13. Paul A., Lapchak, PhD, FAHA, A Critical Assessment Of Edaravone in Acute Ischemic stroke Efficacy trials, Expert Opinion On Pharmacotherapy, July2010-11(10):1753-1763.
14. Ping Liao, Zheng-Yu Yan, Zhi-JiXu, Xiao Sun. A novel fluorescent assay for edaravone with aqueous functional CdSe quantum dots. SpectrochimicaActa Part A: Molecular and Biomolecular Spectroscopy; 2009, 72(5):75
15. Gandhimathi M, Kumar MS, Baghla R and Ravi TK. RP-HPTLC Method for the In Vitro Estimation of Edaravone in Human Plasma. Indian Journal of Pharmaceutical Science; 2010,72(2):276-282.
16. Li jin-linet al. Determination of Phenylhydrazine Residues in Edaravone by HPLC. Institute of Medical Information; CAMS, 2009.
17. Fu Gui-Ying, WEN Ming-Ling, JIA Li-Hua,ZUOXiu-Ping, Determination of content and related substance of edaravone injection by HPLC.; Pharmaceutical Journal Of Chinese people´s Liberation Army.2009-02.101-14
18. WEI Min, XIAO Yi (Guangxi Liuzhou Municipal People´s Hospital, China), Determination of concentration of edaravone in human serum by RP HPLC; Clinical pharmacy 2007-08.142-143
19. Bhumi K.Patel, Hasumati A.Raj, Vineet C.Jain, Simultaneous Estimation of Edaravone and Citicoline sodium by Ratio derivative spectroscopic method in synthetic mixture,; Pharmascience Monitor, An International Journal Of Pharmaceutical Science, 5(2)sup-1 Apr-June 2014,:118-128.
20. Bhumi K Patel, Hasumati A Raj, Vineet C Jain, Vishnu Sutariya, Mihir Bhatt, Kaushik Patel, method development and validation of RP HPLC for simultaneous estimation of edaravone and citicoline sodium in synthetic mixture, inventi rapid: pharm analysis & quality assurance publication date: 2014/5/6.
.png)
